𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial

✍ Scribed by Flanigan, Kevin M.; Voit, Thomas; Rosales, Xiomara Q.; Servais, Laurent; Kraus, John E.; Wardell, Claire; Morgan, Allison; Dorricott, Susie; Nakielny, Joanna; Quarcoo, Naashika; Liefaard, Lia; Drury, Tom; Campion, Giles; Wright, Padraig


Book ID
122185355
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
753 KB
Volume
24
Category
Article
ISSN
0960-8966

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Pharmacokinetics and safety of single do
✍ Flanigan, Kevin M.; Voit, Thomas; Rosales, Xiomara Q.; Servais, Laurent; Kraus, πŸ“‚ Article πŸ“… 2014 πŸ› Elsevier Science 🌐 English βš– 753 KB

Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due to mutations of the dystrophin gene. Drisapersen is a 2β€²-__O__-methyl-phosphorothioate oligonucleotide designed to skip exon 51 in dystrophin pre-mRNA to restore the read

A randomized, double-blind clinical tria
✍ Nicolino Ruperto; Irina Nikishina; Evgueni D. Pachanov; Ynessa Shachbazian; Anne πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 122 KB πŸ‘ 2 views

## Abstract ## Objective In an international, multicenter, double‐blind, randomized clinical trial we evaluated the short‐term (3 months) and long‐term (12 months) efficacy and safety of 2 different doses of meloxicam oral suspension compared with the efficacy and safety of naproxen oral suspensio